Amcenestrant - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of targeted protein degradation research as SK Life Science Labs presents new preclinical p300 and PRMT5 cancer data at AACR 2026.

Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight

Why Cerebras’ IPO filing looks less like a chip listing and more like an AI infrastructure wager

What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence

Lycra launches VintageFX fibre at Kingpins Amsterdam as denim makers chase vintage looks without fit failure

Lycra has spotted denim’s next problem, and VintageFX is its answer

Representative image illustrating PROTAC-mediated targeted protein degradation of the estrogen receptor in ER+ breast cancer, a novel approach used by vepdegestrant to overcome endocrine resistance.

Read More

Pharma Industry News

PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?

Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.

byPallavi Madhiraju

June 9, 2025

web analytics